📋 Tender Overview
The DAK-Gesundheit intends to conclude a non-exclusive discount agreement for the active ingredient Omalizumab, ATC L04AG08, for the period from 01.08.2026 to 31.07.2028. This procedure is based on the absence of a selection decision, allowing all pharmaceutical companies to participate without discrimination. The agreement will automatically end upon the commencement of an exclusive contract for the active ingredient Omalizumab. The DAK-Gesundheit aims to establish discount agreements with as many interested pharmaceutical companies as possible until new discount agreements for medicines come into effect. Omalizumab, ATC L04AG08